SpyGlass Pharma Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

-40m

CFO

-33m

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Key people

Patrick Mooney

Chief Executive Officer · since 2021

Glenn Sussman

Co-Founder, Chief Technology Officer · since 2021

James Dennewill

Chief Operating Officer · since 2021

Malik Kahook

Co-Founder, President, Chief Medical Officer, Executive Chair of the Board and Director · since 2024

URL

https://spyglasspharma.com/

IPO date

Feb 06, 2026

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title in thousands, except ratios and share amounts	FY
Title in thousands, except ratios and share amounts	2025‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT